Zhang Lin, Wang Junxi, Xu Ye, Wei Kaiyan, Lin Wei, Hu Huixiang, Liu Yijuan
Department of Gastrointestinal Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, China.
The First Clinical College of Medicine, Fujian Medical University, Fuzhou, 350005, China.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jan 22. doi: 10.1007/s00210-025-03787-8.
Ulcerative colitis (UC) remains an intractable and relapsing disease featured by intestinal inflammation. The anti-UC activity of Akkermansia muciniphila (AKK), an intestinal microorganism, has been widely investigated. The current work is to explore the impacts of AKK on UC and its possible reaction mechanism. In vivo UC model was induced by dextran sulfate sodium (DSS) and phorbol-12-myristate-13-acetate (PMA)-induced THP-1-M0 and raw264.7 macrophages were treated by lipopolysaccharide (LPS). H&E staining evaluated tissue damage. Inflammatory and oxidative stress levels were assessed by relevant kits. The high-throughput analysis of fatty acids was performed by the LC/MS method. RT-qPCR and Western blot detected related gene expression. Flow cytometry measured cell apoptosis and macrophage polarization. Energy metabolism was detected by ELISA, related assay kits, JC-1 staining, and Western blot. AKK reduced the pathological damage of mice colon tissues, alleviated oxidative stress and inflammatory response, upregulated the expression of Occludin-1 and SCFAs receptors, and stimulated M1 to M2 macrophage polarization in vivo. After FFAR2 was silenced, the promoting role of AKK in the viability and M1 to M2 macrophage polarization and the inhibitory role in oxidative stress, inflammation, apoptosis, energy metabolism disorder, necroptosis, and pyroptosis were both reverted. Conclusively, AKK might mediate SCFAs-SLC52A2/FFAR2 pathways to exert protective activities against intestinal inflammatory response in UC, suggesting that AKK might represent a novel and promising candidate for UC therapy.
溃疡性结肠炎(UC)仍然是一种以肠道炎症为特征的难治性复发性疾病。肠道微生物嗜黏蛋白阿克曼氏菌(AKK)的抗UC活性已得到广泛研究。当前的工作是探索AKK对UC的影响及其可能的反应机制。通过葡聚糖硫酸钠(DSS)诱导建立体内UC模型,并用脂多糖(LPS)处理佛波醇-12-肉豆蔻酸酯-13-乙酸酯(PMA)诱导的THP-1-M0和raw264.7巨噬细胞。苏木精-伊红(H&E)染色评估组织损伤。通过相关试剂盒评估炎症和氧化应激水平。采用液相色谱/质谱(LC/MS)法对脂肪酸进行高通量分析。实时定量聚合酶链反应(RT-qPCR)和蛋白质免疫印迹法检测相关基因表达。流式细胞术检测细胞凋亡和巨噬细胞极化。通过酶联免疫吸附测定(ELISA)、相关检测试剂盒、JC-1染色和蛋白质免疫印迹法检测能量代谢。AKK减轻了小鼠结肠组织的病理损伤,缓解了氧化应激和炎症反应,上调了闭合蛋白-1(Occludin-1)和短链脂肪酸(SCFAs)受体的表达,并在体内刺激了M1向M2巨噬细胞极化。在游离脂肪酸受体2(FFAR2)沉默后,AKK对细胞活力和M1向M2巨噬细胞极化的促进作用以及对氧化应激、炎症、凋亡、能量代谢紊乱、坏死性凋亡和炎性小体凋亡的抑制作用均被逆转。总之,AKK可能通过介导SCFAs-SLC52A2/FFAR2通路发挥对UC肠道炎症反应的保护作用,提示AKK可能是UC治疗的一种新的有前景的候选物。